Skip to main content
Xspray Pharma logo

Xspray Pharma — Investor Relations & Filings

Ticker · XSPRAY ISIN · SE0023312764 LEI · 549300NGRQCNZ3X4L157 ST Manufacturing
Open in API
Filings indexed 254 across all filing types
Latest filing 2026-02-26 Board/Management Inform…
Country SE Sweden
Listing ST XSPRAY

About Xspray Pharma

https://xspraypharma.com/

Xspray Pharma is a pharmaceutical company that utilizes its patented technology platform to develop improved versions of marketed drugs, primarily focusing on Protein Kinase Inhibitors (PKIs) for cancer treatment. The company's core innovation lies in its ability to create stable, amorphous (non-crystalline) formulations of active pharmaceutical ingredients. This unique approach enables the development of product candidates that can bypass the secondary patents of original crystalline drugs, facilitating market entry upon the expiration of the primary substance patent. Xspray Pharma's products are designed to offer clinical benefits for patients compared to the original branded drugs and their subsequent generic equivalents.

Recent filings

Filing Released Lang Actions
Xspray Pharma utser Blake Leitch till VD – Per Andersson fortsätter som forskningschef (CSO)
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new CEO (Blake Leitch) and the transition of the current CEO (Per Andersson) to the role of Chief Scientific Officer (CSO) at Xspray Pharma. This falls directly under the category of management changes, which is defined as 'Announcement of changes in the company's board of directors or senior management'.
2026-02-26 Swedish
Xspray Pharma appoints Blake Leitch as CEO – Per Andersson continues as Chief Scientific Officer (CSO)
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new CEO and the transition of the current CEO to a CSO role. This falls under the category of board and management changes. The document is clearly an announcement of these changes rather than a formal regulatory filing or a report itself.
2026-02-26 English
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period October-December 2025, published by Xspray Pharma. It contains comprehensive financial data, including income statements, cash flow summaries, key performance indicators (Nyckeltal), and management commentary (VD har ordet). It is not a mere announcement or certification, but the full interim financial report itself, fitting the definition of an Interim/Quarterly Report (IR). Q4 2025
2026-02-12 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report October – December 2025' and contains comprehensive financial statements, key performance indicators, management commentary (CEO message), and operational updates for the specified period. It is a full financial report for a period shorter than a fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q4 2025
2026-02-12 English
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport Juli - september 2025' (Interim Report July - September 2025). It contains comprehensive financial data, including income statements, cash flow analysis, key performance indicators (Nyckeltal), and management commentary (VD har ordet) for the specified quarterly period. It is a substantive financial report rather than an announcement or a certification, fitting the definition of an Interim/Quarterly Report. 9M 2025
2025-11-05 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report July - September 2025' and contains comprehensive financial data, including key figures for the group, income statements, cash flow analysis, and management commentary on business performance and outlook. It covers a period shorter than a full fiscal year (Q3 2025), fitting the definition of an Interim/Quarterly Report. 9M 2025
2025-11-05 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.